Humane Genomics · Jan 2026
Technical update on aptazyme-based selective replication, including validation of an RNA ON-switch and prototype virus HGI536.
A platform to make artificial viruses as cancer therapeutics.
Company research
Public company, workplace, funding, and market signals
Overview
New York City biotech developing precision synthetic oncolytic RNA virus therapies for cancer, with a lead focus on pediatric liver cancer.
Primary product
Precision oncolytic virus therapy platform (lead program HGI627)
Founded
2019
Headquarters
180 Varick Street, Floor 6, New York, NY 10014, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Oncolytic virotherapy / synthetic biology
Offices
180 Varick Street, Floor 6, New York, NY 10014, United States
Open Positions
0 jobs at Humane Genomics
No open positions
Check back later for new openings